SUPN
Supernus Pharmaceuticals Inc
42.00$
-2.1%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +18.3% | +48.9% | +40.6% | +35.3% | -3.9% | +32.5% | +11.4% | +15.1% | -8.9% | +8.9% | +8.6% | |
| – | +46.3% | +42.3% | +26.9% | +0.9% | +8.5% | +214.9% | +43.1% | +16.2% | -3.9% | -7.0% | -4.3% | |
| – | +17.0% | +49.3% | +41.4% | +37.1% | -4.4% | +24.4% | +7.9% | +14.9% | -9.7% | +11.5% | +10.4% | |
| – | +48.8% | +46.9% | +15.9% | +79.9% | -22.5% | +9.9% | +19.1% | -17.6% | +22.9% | +18.8% | -2.4% | |
| – | +21.2% | +20.3% | +23.8% | +12.0% | +0.9% | -44.0% | +59.4% | +4.2% | +116.3% | +4.5% | -20.4% | |
| – | +28.5% | +25.7% | +26.0% | +32.9% | -8.7% | +29.3% | +42.3% | +27.5% | -0.9% | -5.1% | +35.6% | |
| – | -27.1% | +206.9% | +83.6% | +45.1% | +2.9% | +16.9% | -50.5% | -46.4% | -111.4% | – | -145.1% | |
| – | -15.1% | +6.7% | -69.2% | +1,055.0% | +25.4% | +4.6% | -1.4% | -69.8% | -65.8% | -100.0% | – | |
| – | -24.7% | +236.4% | +99.8% | +39.3% | +5.2% | +14.3% | -56.6% | -17.0% | -95.4% | +3,434.5% | -150.1% | |
| – | -76.3% | -4,373.2% | – | -32.7% | +18.0% | +21.1% | -52.6% | -99.8% | +4,440.6% | +1,552.1% | -143.7% | |
| – | -29.5% | +550.8% | -37.2% | +93.8% | +1.9% | +12.3% | -57.9% | +13.6% | -97.8% | +5,512.8% | -152.2% | |
| – | – | +160.1% | +90.2% | +40.7% | +19.1% | +16.7% | -38.6% | +18.7% | -41.3% | +98.0% | -76.1% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.